Histamine, a vasoactive agent with vascular disrupting potential, improves tumour response by enhancing local drug delivery

British Journal of Cancer

Volumn 95, Issue 12, 2006, Pages 1663-1669

  Brunstein, F ^a   Rens, J ^a   Van Tiel, S T ^a   Eggermont, A M M ^a   Ten Hagen, T L M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Doxorubicin; Histamine; Regional treatment; Soft tissue sarcomas; TAV

Indexed keywords

ANTIINFECTIVE AGENT; DOXORUBICIN; HISTAMINE; VASCULAR TARGETING AGENT; VASOACTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL LEVEL; DISEASE COURSE; DRUG DELIVERY SYSTEM; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; LIMB PERFUSION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SOFT TISSUE SARCOMA; TUMOR CELL; TUMOR GROWTH; TUMOR VASCULARIZATION; UMBILICAL VEIN;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CARDIOVASCULAR AGENTS; CELLS, CULTURED; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; DOXORUBICIN; DRUG DELIVERY SYSTEMS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ENDOTHELIUM, VASCULAR; HINDLIMB; HISTAMINE; HUMANS; MALE; RATS; RATS, INBRED BN; SARCOMA; UMBILICAL VEINS;

EID: 33845615922     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603461     Document Type: Article

References (30)

1. Bancroft JD, Cook HC (1984) Manual of Histological Techniques and their Diagnostic Application ISBN: 0 443 02870 2
2. Bickels J, Manusama ER, Gutman M, Eggermont AM, Kollender Y, Abu-Abid S, van Geel AN, Lev-Shlush D, Klausner JM, Meller I (1999) Isolated limb perfusion with tumour necrosis factor-alpha and melphalan for unresectable bone sarcomas of the lower extremity. Eur J Surg Oncol 25: 509-514
3. Brunstein F, Hoving S, Seynhaeve AL, van Tiel ST, Guetens G, de Bruijn EA, Eggermont AM, ten Hagen TL (2004) Synergistic antitumor activity of histamine plus melphalan in isolated limb perfusion: preclinical studies. J Natl Cancer Inst 96: 1603-1610
4. Carson MR, Shasby SS, Shasby DM (1989) Histamine and inositol phosphate accumulation in endothelium: cAMP and a G protein. Am J Physiol 257: L259-L264
5. Denekamp J (1984) Vascular endothelium as the vulnerable element in tumours. Acta Radiol Oncol 23: 217-225
6. de Wilt JH, Manusama ER, van Tiel ST, van IJken MG, ten Hagen TL, Eggermont AM (1999) Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats. Br J Cancer 80: 161-166
7. de Wilt JH, ten Hagen TL, de Boeck G, van Tiel ST, de Bruijn EA, Eggermont AM (2000) Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion. Br J Cancer 82: 1000-1003
8. Eggermont AM, de Wilt JH, ten Hagen TL (2003) Current uses of isolated limb perfusion in the clinic and a model system for new strategies. Lancet Oncol 4: 429-437
9. Eggermont AM, Schraffordt KH, Klausner JM, Eggermont AM, Schraffordt Koops H, Klausner JM, Kroon BB, Schlag PM, Lienard D, van Geel AN, Hoekstra HJ, Meller I, Nieweg OE, Kettelhack C, Ben-Ari G, Pector JC, Lejeune FJ (1996a) Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg 224: 756-764
10. Eggermont AM, Schraffordt KH, Lienard D, Kroon BB, van Geel AN, Hoekstra HJ, Lejeune FJ (1996b) Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol 14: 2653-2665
11. Hoving S, Brunstein F, aan de Wiel-Ambagtsheer G, van Tiel ST, de Boeck G, de Bruijn EA, Eggermont AM, ten Hagen TL (2005) Synergistic antitumor response of interleukin 2 with melphalan in isolated limb perfusion in soft tissue sarcoma-bearing rats. Cancer Res 65(10): 4300-4308
12. Hoving S, Seynhaeve AL, van Tiel ST, aan de Wiel-Ambagtsheer G, de Bruijn EA, Eggermont AM, ten Hagen TL (2006) Early destruction of tumor vasculature in tumor necrosis factor-alpha-based isolated limb perfusion is responsible for tumor response. Anticancer Drugs 17: 949-959
13. Kort WJ, Zondervan PE, Hulsman LO, Weijma IM, Westbroek DL (1984) Incidence of spontaneous tumors in a group of retired breeder female brown Norway rats. J Natl Cancer Inst 72: 709-713
14. Lienard D, Lejeune FJ, Ewalenko P (1992) In transit metastases of malignant melanoma treated by high dose rTNF alpha in combination with interferon-gamma and melphalan in isolation perfusion. World J Surg 16: 234-240
15. Nooijen PT, Manusama ER, Eggermont AM, Schalkwijk L, Stavast J, Marquet RL, de Waal RMW, Ruiter DJ (1996) Synergistic effects of TNF-alfa and melphalan in an isolated limb perfusion model of rat sarcoma: a histopathological, immunohistochemical and electron microscopical study. Br J Cancer 74: 1908-1915
16. O'Byrne K, Steward WP (1999) The role of chemotherapy in the treatment of adult soft tissue sarcomas. Oncology 56: 13-23
17. Olieman AF, Lienard D, Eggermont AM, Kroon BB, Lejeune FJ, Hoekstra HJ, Koops HS (1999) Hyperthermic isolated limb perfusion with tumor necrosis factor alpha, interferon gamma, and melphalan for locally advanced nonmelanoma skin tumors of the extremities: a multicenter study. Arch Surg 134: 303-307
18. Primeau AJ, Rendon A, Hedley D, Lilge L, Tannock IF (2005) The distribution of the anticancer drug doxorubicin in relation to blood vessels in solid tumors. Clin Cancer Res 11: 8782-8788
19. Resink TJ, Grigorian GY, Moldabaeva AK, Danilov SM, Buhler FR (1987) Histamine-induced phosphoinositide metabolism in cultured human umbilical vein endothelial cells. Association with thromboxane and prostacyclin release. Biochem Biophys Res Commun 144: 438-446
20. Revtyak GE, Campbell WB (1992) Inhibition of prostaglandin synthesis in human endothelial cells treated with metabolic inhibitors. Biochim Biophys Acta 1123: 216-226
21. Rossi CR, Foletto M, Di Filippo F, Vaglini M, Anza' M, Azzarelli A, Pilati P, Mocellin S, Lise M (1999) Soft tissue limb sarcomas: Italian clinical trials with hyperthermic antiblastic perfusion. Cancer 86: 1742-1749
22. Rossi CR, Mocellin S, Pilati P, Foletto M, Campana L, Quintieri L, De Salvo GL, Lise M (2005) Hyperthermic isolated perfusion with low-dose tumor necrosis factor α and doxorubicin for the treatment of limb-threatening soft tissue sarcomas. Ann Surg Oncol 12(5): 1-8
23. Santoro A, Tursz T, Mouridsen H, Verweij J, Steward W, Somers R, Buesa J, Casali P, Spooner D, Rankin E, Kirkpatrick A, van Glabbeke M, van Oosterom A (1995) Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 13: 1537-1545
24. Seynhaeve AL, Vermeulen CE, Eggermont AM, ten Hagen TL (2006) Cytokines and vascular permeability: an in vitro study on human endothelial cells in relation to tumor necrosis factor-alphaprimed peripheral blood mononuclear cells. Cell Biochem Biophys 44: 157-169
25. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82: 1107-1112
26. Takemoto M, Kuroda M, Urano M, Nishimura Y, Kawasaki S, Kato H, Okumura Y, Akaki S, Kanazawa S, Asaumi J, Joja I, Hiraki Y (2003) The effect of various chemotherapeutic agents given with mild hyperthermia on different types of tumours. Int J Hyperthermia 19: 193-203
27. Thompson JF, Kam PC, Waugh RC, Harman CR (1998) Isolated limb infusion with cytotoxic agents: a simple alternative to isolated limb perfusion. Semin Surg Oncol 14: 238-247
28. van de Wiel PA, Weitenberg ES, van der PA, Bloksma N (1992) Factors that define the susceptibility of endothelial cells to tumor necrosis factor and lipid A. Immunopharmacology 23: 49-56
29. Wang L, Kaduce TL, Spector AA (1990) Localization of 12- hydroxyeicosatetraenoic acid in endothelial cells. J Lipid Res 31: 2265-2276
30. Wu NZ, Baldwin AL (1992) Possible mechanism(s) for permeability recovery of venules during histamine application. Microvasc Res 44: 334-352